In aspects, a cannabis extract enriched in polyphenolic compounds is provided herein. Also provided herein is a method for enriching a composition with polyphenolic compounds as well as compositions made by the method. Various cosmetic and pharmaceutical products, methods, and uses are provided herein as well as natural health products.

In aspects, a cannabis extract enriched in polyphenolic compounds is provided herein. Also provided herein is a method for enriching a composition with polyphenolic compounds as well as compositions made by the method. Various cosmetic and pharmaceutical products, methods, and uses are provided herein as well as natural health products.

Cannabinoids are used to treat diseases or disorders treatable by an activator of the A.sub.3 adenosine receptor (A.sub.3AR). The cannabinoid effect is exerted through the A3AR. The cannabinoids may be selected from natural, phytocannabinoids, synthetic derivatives of phytocannabinoids, extracts of cannabis plant, and others.

Cannabinoids are used to treat diseases or disorders treatable by an activator of the A.sub.3 adenosine receptor (A.sub.3AR). The cannabinoid effect is exerted through the A3AR. The cannabinoids may be selected from natural, phytocannabinoids, synthetic derivatives of phytocannabinoids, extracts of cannabis plant, and others.

Cannabinoids are used to treat diseases or disorders treatable by an activator of the A.sub.3 adenosine receptor (A.sub.3AR). The cannabinoid effect is exerted through the A3AR. The cannabinoids may be selected from natural, phytocannabinoids, synthetic derivatives of phytocannabinoids, extracts of cannabis plant, and others.

The present invention relates to a composition comprising 4-hexylresorcinol(4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The present invention relates to a composition comprising 4-hexylresorcinol(4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

Methods and compositions for preventing sympathetic activation resulting from administration of a TRPV1 modulator alone. Methods include co-administering QX-314 and a TRPV1 modulator to prevent sympathetic activation resulting from administration of a TRPV1 modulator alone comprising administering QX-314 and the TRPV1 modulator to a subject in need thereof. Compositions include a composition to prevent sympathetic activation comprising QX-314 and a TRPV1 modulator.

Methods and compositions for preventing sympathetic activation resulting from administration of a TRPV1 modulator alone. Methods include co-administering QX-314 and a TRPV1 modulator to prevent sympathetic activation resulting from administration of a TRPV1 modulator alone comprising administering QX-314 and the TRPV1 modulator to a subject in need thereof. Compositions include a composition to prevent sympathetic activation comprising QX-314 and a TRPV1 modulator.

Methods and compositions for preventing sympathetic activation resulting from administration of a TRPV1 modulator alone. Methods include co-administering QX-314 and a TRPV1 modulator to prevent sympathetic activation resulting from administration of a TRPV1 modulator alone comprising administering QX-314 and the TRPV1 modulator to a subject in need thereof. Compositions include a composition to prevent sympathetic activation comprising QX-314 and a TRPV1 modulator.